Renzo Cordera

List of Publications by Year
in descending order

117	3,167	136740	168136
papers	citations	32 h-index	53 g-index

119	119	119	4117
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Diabetes Resolution at 10 Years After Biliopancreatic Diversion in Overweight and Class 1 Obese Patients with Type 2 Diabetes. Obesity Surgery, 2022, 32, 845-851.	1.1	2
2	Insulin action in subjects with type 2 diabetes following biliopancreatic diversion. European Journal of Clinical Investigation, 2022, 52, e13727.	1.7	1
3	miR-126 Mimic Counteracts the Increased Secretion of VEGF-A Induced by High Glucose in ARPE-19 Cells. Journal of Diabetes Research, 2021, 2021, 1-7.	1.0	5
4	Prediction of Type 2 Diabetes Remission at Long-term Following Biliopancreatic Diversion: the Relative Role of Different Metabolic Attitudes. Obesity Surgery, 2021, 31, 4159-4160.	1.1	0
5	Antiapolipoprotein A-1 Autoantibody Positivity Is Associated with Threatened Abortion. BioMed Research International, 2020, 2020, 1-8.	0.9	0
6	Type 1 diabetes and technology at time of COVIDâ€19: A case report. European Journal of Clinical Investigation, 2020, 50, e13290.	1.7	0
7	Glycosylated haemoglobin (A1c) best values for type 2 diabetes in the battlefield much ado about nothing? (apparently). Diabetology and Metabolic Syndrome, 2019, 11, 48.	1.2	5
8	Adipose Tissue Composition in Obesity and After Bariatric Surgery. Obesity Surgery, 2019, 29, 3030-3038.	1.1	16
9	Baseline neutrophil-to-lymphocyte ratio is associated with long-term T2D remission after metabolic surgery. Acta Diabetologica, 2019, 56, 741-748.	1.2	15
10	Advanced Glycation End-Products and Hyperglycemia Increase Angiopoietin-2 Production by Impairing Angiopoietin-1-Tie-2 System. Journal of Diabetes Research, 2019, 2019, 1-7.	1.0	11
11	Bariatric or Metabolic Surgery?. Obesity Surgery, 2019, 29, 303-303.	1.1	1
12	Type 2 Diabetes Remission and Control in Overweight and in Mildly Obese Diabetic Patients at Long-Term Follow-Up After Biliopancreatic Diversion. Obesity Surgery, 2019, 29, 239-245.	1.1	12
13	Serum levels of osteopontin predict diabetes remission after bariatric surgery. Diabetes and Metabolism, 2019, 45, 356-362.	1.4	20
14	Levels of serum uric acid at admission for hypoglycaemia predict 1-year mortality. Acta Diabetologica, 2018, 55, 323-330.	1.2	5
15	Switching from Glargine to Degludec is not associated with an overt change in glucose control in a cohort of patients with type 1 diabetes: a CGM analysis. Acta Diabetologica, 2018, 55, 637-639.	1.2	0
16	Dietary intake and major food sources of polyphenols in people with type 2 diabetes: The TOSCA.IT Study. European Journal of Nutrition, 2018, 57, 679-688.	1.8	38
17	C-Reactive Protein Levels at the Midpregnancy Can Predict Gestational Complications. BioMed Research International, 2018, 2018, 1-8.	0.9	21
18	Skin and diabetes: an experts' opinion from the Italian diabetologists and dermatologists of the DiaDex group. Giornale Italiano Di Dermatologia E Venereologia, 2018, 153, 649-658.	0.8	2

#	Article	IF	Citations
19	Universal versus risk factor screening for gestational diabetes mellitus. Clinical and Experimental Obstetrics and Gynecology, 2018, 45, 53-57.	0.1	0
20	Prediction of Diabetes Remission at Long Term Following Biliopancreatic Diversion. Obesity Surgery, 2017, 27, 1705-1708.	1.1	16
21	High baseline C-reactive protein levels predict partial type 2 diabetes mellitus remission after biliopancreatic diversion. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 423-429.	1.1	11
22	Assessing the Actual Clinical Effectiveness of Metabolic/Bariatric Surgery for the Type 2 Diabetes Therapy. Obesity Surgery, 2017, 27, 1886-1888.	1.1	1
23	The interplay between diabetes, depression and affective temperaments: A structural equation model. Journal of Affective Disorders, 2017, 219, 64-71.	2.0	23
24	Glibenclamide Mimics Metabolic Effects of Metformin in H9c2 Cells. Cellular Physiology and Biochemistry, 2017, 43, 879-890.	1.1	13
25	Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 887-897.	5.5	231
26	Early reduction of matrix metalloproteinase-8 serum levels is associated with leptin drop and predicts diabetes remission after bariatric surgery. International Journal of Cardiology, 2017, 245, 257-262.	0.8	19
27	Glucose-targeted therapy for subjects with type 2 diabetes mellitus: primum non nocere. European Journal of Clinical Investigation, 2017, 47, 691-693.	1.7	0
28	Low serum C-reactive protein levels predict 90-day mortality in hypoglycaemic patients. Diabetes and Metabolism, 2017, 43, 554-556.	1.4	4
29	Data-driven strategies for robust forecast of continuous glucose monitoring time-series. , 2017, 2017, 1680-1683.		7
30	The economic burden of severe hypoglycemia: Two sides of the same coin. Comment on G. Veronese and Coll. Costs associated with emergency care and hospitalization for severe hypoglycemia. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 850-851.	1.1	2
31	Adipokine Pattern After Bariatric Surgery: Beyond the Weight Loss. Obesity Surgery, 2016, 26, 2793-2801.	1.1	9
32	Serum Leptin and Adiponectin Concentration in Type 2 Diabetes Patients in the Short and Long Term Following Biliopancreatic Diversion. Obesity Surgery, 2016, 26, 2442-2448.	1.1	17
33	Long-term clinical and functional impact of biliopancreatic diversion on type 2 diabetes in morbidly and nonâ€“morbidly obese patients. Surgery for Obesity and Related Diseases, 2016, 12, 822-827.	1.0	14
34	From bariatric to metabolic surgery: Looking for a â€œdisease modifierâ€•surgery for type 2 diabetes. World Journal of Diabetes, 2016, 7, 27.	1.3	12
35	HOMA, BMI, and Serum Leptin Levels Variations during Antiviral Treatment Suggest Virus-Related Insulin Resistance in Noncirrhotic, Nonobese, and Nondiabetic Chronic Hepatitis C Genotype 1 Patients. Gastroenterology Research and Practice, 2015, 2015, 1-7.	0.7	3
36	IGF1 regulates PKM2 function through Akt phosphorylation. Cell Cycle, 2015, 14, 1559-1567.	1.3	42

#	Article	IF	Citations
37	Comment on Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140â€“149. Diabetes Care, 2015, 38, e125-e126.	4.3	3
38	Impaired Increase of Plasma Abscisic Acid in Response to Oral Glucose Load in Type 2 Diabetes and in Gestational Diabetes. PLoS ONE, 2015, 10, e0115992.	1.1	31
39	Effects of Gastric Bypass on Type 2 Diabetes in Patients with BMI 30 to 35. Obesity Surgery, 2014, 24, 1036-1043.	1.1	24
40	Metformin, cancer and glucose metabolism. Endocrine-Related Cancer, 2014, 21, R461-R471.	1.6	91
41	Appetite control and gastrointestinal hormonal behavior (CCK, GLP-1, PYY 1â€“36) following low doses of a whey protein-rich nutraceutic. Mediterranean Journal of Nutrition and Metabolism, 2013, 6, 259-266.	0.2	16
42	Tissue specificity in fasting glucose utilization in slightly obese diabetic patients submitted to bariatric surgery. Obesity, 2013, 21, E175-81.	1.5	8
43	Comments on ORIGIN trial. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, e33-e34.	1.1	0
44	Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer. Cell Cycle, 2013, 12, 3490-3499.	1.3	124
45	Metformin Impairs Glucose Consumption and Survival in Calu-1 Cells by Direct Inhibition of Hexokinase-II. Scientific Reports, 2013, 3, 2070.	1.6	100
46	Caveolin-1 and polymerase I and transcript release factor: new players in insulin-like growth factor-I receptor signaling. Journal of Endocrinological Investigation, 2013, 36, 204-8.	1.8	6
47	Caveolinâ€1 is essential for metformin inhibitory effect on IGF1 action in nonâ€smallâ€cell lung cancer cells. FASEB Journal, 2012, 26, 788-798.	0.2	64
48	The plant hormone abscisic acid increases in human plasma after hyperglycemia and stimulates glucose consumption by adipocytes and myoblasts. FASEB Journal, 2012, 26, 1251-1260.	0.2	81
49	Effects of Biliopanceratic Diversion on Type 2 Diabetes in Patients With BMI 25 to 35. Annals of Surgery, 2011, 253, 699-703.	2.1	88
50	The Effects of Biliopancreatic Diversion on Type 2 Diabetes Mellitus in Patients with Mild Obesity (BMI) Tj ETQq0 0 0 rgBT /Overlock 10 T Surgery, 2011, 21, 880-888.	1.1	79
51	Optimization of flow reserve measurement using SPECT technology to evaluate the determinants of coronary microvascular dysfunction in diabetes. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 357-367.	3.3	17
52	Î²â€Cell Function Improvement After Biliopancreatic Diversion in Subjects With Type 2 Diabetes and Morbid Obesity. Obesity, 2010, 18, 932-936.	1.5	31
53	Changes in adiponectin and leptin concentrations during glucocorticoid treatment: a pilot study in patients with polymyalgia rheumatica. Annals of the New York Academy of Sciences, 2010, 1193, 160-163.	1.8	14
54	IGF-IR Internalizes with Caveolin-1 and PTRF/Cavin in Hacat Cells. PLoS ONE, 2010, 5, e14157.	1.1	43

#	Article	IF	Citations
55	Insulin analogues: fears, facts and fantasies. Diabetes/Metabolism Research and Reviews, 2009, 25, 50-51.	1.7	2
56	Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity and Metabolism, 2009, 11, 611-622.	2.2	272
57	IGF-I induced rapid recruitment of integrin Î²1 to lipid rafts is Caveolin-1 dependent. Biochemical and Biophysical Research Communications, 2009, 380, 489-492.	1.0	18
58	Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 571-579.	1.1	40
59	Hypoadiponectinemia in lipodystrophic HIV individuals: A metabolic marker of subclinical cardiac damage. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 277-282.	1.1	11
60	Restoration of Acute Insulin Response in T2DM Subjects 1 Month After Biliopancreatic Diversion. Obesity, 2008, 16, 77-81.	1.5	55
61	Leptin, Ghrelin, and Adiponectin Evaluation in Transsexual Subjects During Hormonal Treatments. Journal of Andrology, 2008, 29, 580-585.	2.0	15
62	Caveolin-1 is essential for glimepiride-induced insulin secretion in the pancreatic Î²TC-6 cell line. Biochemical and Biophysical Research Communications, 2008, 375, 235-237.	1.0	5
63	Caveolin-1 Down-Regulation Inhibits Insulin-Like Growth Factor-I Receptor Signal Transduction in H9C2 Rat Cardiomyoblasts. Endocrinology, 2008, 149, 461-465.	1.4	35
64	Effects of Pioglitazone in Combination with Metformin or a Sulfonylurea Compared to a Fixed-Dose Combination of Metformin and Glibenclamide in Patients with Type 2 Diabetes. Diabetes Technology and Therapeutics, 2007, 9, 387-398.	2.4	16
65	Alterations in the autonomic control of heart rate variability in patients with anorexia or bulimia nervosa: Correlations between sympathovagal activity, clinical features, and leptin levels. Journal of Endocrinological Investigation, 2007, 30, 356-362.	1.8	69
66	Effect of two fasting periods of different duration on ghrelin response to a mixed meal. Nutrition, Metabolism and Cardiovascular Diseases, 2006, 16, 471-476.	1.1	11
67	High-Molecular Weight Adiponectin Isoforms Increase after Biliopancreatic Diversion in Obese Subjects*. Obesity, 2006, 14, 1511-1514.	1.5	51
68	Glimepiride activates eNOS with a mechanism Akt but not caveolin-1 dependent. Biochemical and Biophysical Research Communications, 2005, 335, 832-835.	1.0	16
69	Insulin and IGF-I phosphorylate eNOS in HUVECs by a caveolin-1 dependent mechanism. Biochemical and Biophysical Research Communications, 2005, 337, 849-852.	1.0	39
70	Long-term normalization of insulin sensitivity following biliopancreatic diversion for obesity. International Journal of Obesity, 2004, 28, 671-673.	1.6	23
71	Changes in Serum Ghrelin Concentration following Biliopancreatic Diversion for Obesity. Obesity, 2004, 12, 684-687.	4.0	48
72	Reduction of cardiovascular morbidity and mortality in Type 2 diabetes. A rational approach to hypoglycemic therapy. Journal of Endocrinological Investigation, 2004, 27, 485-495.	1.8	5

#	Article	IF	Citations
73	IGF-I regulates caveolin 1 and IRS1 interaction in caveolae. Biochemical and Biophysical Research Communications, 2004, 316, 240-243.	1.0	28
74	Plasma Ghrelin Concentratin in the Short-Term following Biliopancreatic Diversion. Obesity Surgery, 2003, 13, 889-892.	1.1	57
75	Recovery of insulin sensitivity in obese patients at short term after biliopancreatic diversion. Journal of Surgical Research, 2003, 113, 217-221.	0.8	40
76	Association of body mass index, physical activity and eating pattern in adult men. Nutrition Research, 2003, 23, 579-583.	1.3	5
77	Acute plasma glucose increase, but not early insulin response, regulates plasma ghrelin. European Journal of Endocrinology, 2003, 149, 403-406.	1.9	39
78	The extracellular portion of the insulin receptor beta-subunit regulates the cellular trafficking of the insulin-insulin receptor complex. Studies on Chinese hamster ovary cells carrying the Cys 860-->Ser insulin receptor mutation. European Journal of Endocrinology, 2003, 148, 365-371.	1.9	3
79	Specificity of Insulin-Like Growth Factor I and Insulin on Shc Phosphorylation and Grb2 Recruitment in Caveolae. Endocrinology, 2003, 144, 5497-5503.	1.4	38
80	IGF-I induces caveolin 1 tyrosine phosphorylation and translocation in the lipid rafts. Biochemical and Biophysical Research Communications, 2002, 295, 1085-1089.	1.0	49
81	Cys 786 and Cys 776 in the Posttranslational Processing of the Insulin and IGF-I Receptors. Biochemical and Biophysical Research Communications, 2001, 280, 836-841.	1.0	5
82	Sulfonylurea Treatment of Type 2 Diabetic Patients Does Not Reduce the Vasodilator Response to Ischemia. Diabetes Care, 2001, 24, 738-742.	4.3	22
83	Serum leptin concentrations during the menstrual cycle in normal-weight women: effects of an oral triphasic estrogen-progestin medication. European Journal of Endocrinology, 2000, 142, 174-178.	1.9	57
84	Role of proline 193 in the insulin receptor post-translational processing. Diabetologia, 1999, 42, 435-442.	2.9	5
85	Evaluation of growth hormone administration in patients with chronic heart failure secondary to coronary artery disease. American Journal of Cardiology, 1999, 84, 430-433.	0.7	48
86	Role of IRS-1 and SHC activation in 3T3-L1 fibroblasts differentiation. Growth Hormone and IGF Research, 1998, 8, 363-367.	0.5	7
87	Toxic thyroid adenoma: absence of DNA mutations of the TSH receptor and Gs alpha. European Journal of Endocrinology, 1998, 138, 37-40.	1.9	6
88	Cys860 in the Extracellular Domain of Insulin Receptor Î²-Subunit Is Critical for Internalization and Signal Transduction*. Endocrinology, 1998, 139, 496-504.	1.4	18
89	The Human Skeletal Muscle Glycogenin Gene: cDNA, Tissue Expression, and Chromosomal Localization. Biochemical and Biophysical Research Communications, 1996, 220, 72-77.	1.0	20
90	Insulin-like growth factor-1 and angiographically documented coronary artery disease. American Journal of Cardiology, 1996, 77, 200-202.	0.7	107

#	Article	IF	Citations
91	P-35: CYS 860 in the insulin receptor ÃŸ subunit is critical for signal transduction in transfected CHO cells. Experimental and Clinical Endocrinology and Diabetes, 1996, 104, 99-100.	0.6	0
92	A Ser for Cys Mutation in the Extracellular Portion of Insulin Receptor Î²-Subunit Impairs the Insulin-Insulin Receptor Complex Internalization in CHO Cells. Biochemical and Biophysical Research Communications, 1995, 210, 931-937.	1.0	5
93	Association between plasma insulin and angiographically documented significant coronary artery disease. American Journal of Cardiology, 1994, 74, 177-179.	0.7	12
94	The Overexpression of Insulin Receptor Makes CHO Cells Resistant to the Action of IGF-1: Role of IRS-1. Biochemical and Biophysical Research Communications, 1994, 205, 693-699.	1.0	7
95	Linkage analysis does not support a role for glucokinase gene in the aetiology of type 2 diabetes mellitus among North Western Italians. Molecular and Cellular Endocrinology, 1994, 104, 147-151.	1.6	0
96	Regional Cerebral Blood Flow and Cerebrovascular Reactivity in IDDM. Diabetes Care, 1993, 16, 462-468.	4.3	52
97	Substitution of Leu for Pro-193 in the insulin receptor in a patient with a genetic form of severe insulin resistance. Human Molecular Genetics, 1993, 2, 1437-1441.	1.4	23
98	Effect ofin VivoVanadate Treatment on Insulin Receptor Tyrosine Kinase Activity in Partially Pancreatectomized Diabetic Rats*. Endocrinology, 1990, 126, 2177-2183.	1.4	31
99	Effect of metformin treatment on insulin action in diabetic rats: In vivo and in vitro correlations. Metabolism: Clinical and Experimental, 1990, 39, 425-435.	1.5	104
100	Antipeptide antibodies toward the extracellular domain of insulin receptor beta-subunit. Biochemical and Biophysical Research Communications, 1989, 162, 1236-1243.	1.0	4
101	Effect of two different glucose concentrations on insulin receptor mRNA levels in human hepatoma HepG2 cells. Biochemical and Biophysical Research Communications, 1989, 160, 1415-1420.	1.0	20
102	Direct modulation of insulin receptor protein tyrosine kinase by vanadate and anti-insulin receptor monoclonal antibodies. Biochemical and Biophysical Research Communications, 1988, 152, 1474-1480.	1.0	45
103	Species Specificity of Insulin Binding and Insulin Receptor Protein Tyrosine Kinase Activity*. Endocrinology, 1987, 121, 2007-2010.	1.4	7
104	Effects of Three Lowâ€Dose Oral Contraceptive Formulations on Lipid Metabolism. Acta Obstetricia Et Gynecologica Scandinavica, 1987, 66, 327-332.	1.3	21
105	Regulation of insulin receptor-associated tyrosine kinase by a polyclonal IgG. Molecular and Cellular Endocrinology, 1987, 53, 9-14.	1.6	5
106	Insulin receptor autophosphorylation and kinase activity in streptozotocin diabetic rats. Effect of a short fast. Biochemical and Biophysical Research Communications, 1986, 140, 850-856.	1.0	16
107	Insulin-like growth factor I (IGF I) receptor autophosphorylation and kinase activity. effect of a human polyclonal-antibody (pIgG). Biochemical and Biophysical Research Communications, 1986, 138, 1023-1029.	1.0	2
108	Effect of insulin receptor autophosphorylation on insulin receptor binding. Molecular and Cellular Endocrinology, 1986, 45, 247-252.	1.6	7

#	Article	IF	Citations
109	Increased phosphorylation of ribosomal protein S6 following microinjection of insulin receptor-kinase into Xenopus oocytes. Nature, 1986, 320, 459-461.	13.7	42
110	Influence of Cell Age and Ketoaminic Linkage on Rapid Glycosylation of Hemoglobin in Human Red Cells In Vitro. Hormone and Metabolic Research, 1985, 17, 201-204.	0.7	2
111	Insulin Receptor Regulation in Human Mature Red Cells in vitro. Hormone Research, 1985, 22, 270-275.	1.8	4
112	Substrate specificities of insulin and epidermal growth factor receptor kinases. Biochemical and Biophysical Research Communications, 1985, 127, 254-263.	1.0	53
113	Inhibition of insulin and epidermal growth factor (EGF) receptor autophosphorylation by a human polyclonal IgG. Biochemical and Biophysical Research Communications, 1985, 132, 991-1000.	1.0	10
114	Insulin Binding on MOLT 4 Cells: Effect of a Sulfonylurea. Hormone Research, 1984, 20, 246-251.	1.8	3
115	Exploration of the early insulin response by two small successive loads of I.V. glucose in normal and obese subjects. Acta Diabetologica Latina, 1978, 15, 53-67.	0.2	1
116	I.V. Glucose tolerance test: Correlation between FFA, glucose and IRI in normal, obese and diabetic subjects. Acta Diabetologica Latina, 1978, 15, 259-272.	0.2	5
117	Cys860 in the Extracellular Domain of Insulin Receptor Î²-Subunit Is Critical for Internalization and Signal Transduction. , 0, .		3